KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $1.0 billion as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 28.31% to $1.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.5 billion through Dec 2025, down 28.9% year-over-year, with the annual reading at $1.0 billion for FY2025, 28.31% down from the prior year.
  • Liabilities and Shareholders Equity hit $1.0 billion in Q4 2025 for Vir Biotechnology, down from $1.0 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 billion in Q1 2022 to a low of $1.0 billion in Q4 2025.
  • Historically, Liabilities and Shareholders Equity has averaged $1.8 billion across 5 years, with a median of $1.7 billion in 2024.
  • Biggest five-year swings in Liabilities and Shareholders Equity: surged 154.24% in 2022 and later crashed 32.71% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $2.0 billion in 2021, then skyrocketed by 43.38% to $2.8 billion in 2022, then tumbled by 31.51% to $1.9 billion in 2023, then decreased by 27.11% to $1.4 billion in 2024, then fell by 28.31% to $1.0 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for VIR at $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.2 billion in Q2 2025.